Horizon Discovery Signs License Agreement With Glenmark Pharmaceuticals for GS Knockout CHO Cell Line for Manufacture of Biot...
September 30 2019 - 6:20AM
Business Wire
Glenmark signs full commercial-use license for
Horizon’s gene-edited CHO cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global
leader in the application of gene editing and gene modulation for
cell line engineering, today announced the full commercial
licensing to Glenmark Pharmaceuticals, a global innovative
pharmaceutical company, of its gene-edited Glutamine Synthetase
(“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of
the agreement were based on stringent evaluation of the cell line
by Glenmark to assess its suitability for adoption into the
Company’s biomanufacturing processes.
Martin Bertschinger, Deputy Director of Cell Sciences,
Glenmark, explained: “After extensive evaluation, Horizon’s GS
knockout CHO K1 cell line demonstrated consistently impressive
performance. We generated clones with high levels of productivity
and a favorable stability profile relative to our previous system.
Incorporating this technology into our biomanufacturing processes
enhances our ability to efficiently generate high quality cell
lines.”
“We are extremely encouraged by the adoption of our GS knockout
CHO K1 cell line by Glenmark. This proprietary solution has now
been licensed to over 50 companies globally, which, together with a
number of confirmed Investigational New Drug (IND) filings for
products expressed in the cells, demonstrates increasing industry
acceptance,” commented Dirk Gewert, Business Unit
Director, Horizon Discovery. “These licenses have been taken as
a result of an unmatched combination of high performance,
transparent cell line history, supporting documentation, and
attractive licensing terms. By adopting this approach, Horizon aims
to empower organizations of all sizes from large pharmaceutical
companies to small startups to drive efficiencies in biotherapeutic
manufacturing.”
Horizon licenses its CHO expression system to pharmaceutical,
biotechnology, and biosimilar companies, as well as contract
manufacturing organizations. The system includes the GS knockout
CHO K1 cell line, a comprehensive package of supporting
documentation, and an expression vector supplied under license from
DNATwoPointO, Inc. This biomanufacturing platform allows these
companies to move from the DNA sequence of their potential
biotherapeutic to clinical manufacturing as simply and rapidly as
possible.
For further information on Horizon’s CHO expression system,
please visit:
https://www.horizondiscovery.com/bioproduction/cho-cells
ENDS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190930005350/en/
Zyme Communications (Trade and Regional Media) Katie
Odgaard Tel: +44 (0)7787 502 947 Email:
katie.odgaard@zymecommunications.com
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024